Show simple item record

dc.contributor.authorHuang, Kuan-Chun
dc.contributor.authorYang, Junzheng
dc.contributor.authorNg, Michelle C
dc.contributor.authorNg, Shu-Kay
dc.contributor.authorWelch, William R
dc.contributor.authorMuto, Michael G
dc.contributor.authorBerkowitz, Ross S
dc.contributor.authorNg, Shu-Wing
dc.date.accessioned2018-02-20T00:56:50Z
dc.date.available2018-02-20T00:56:50Z
dc.date.issued2016
dc.identifier.issn0959-8049
dc.identifier.doi10.1016/j.ejca.2016.08.007
dc.identifier.urihttp://hdl.handle.net/10072/100459
dc.description.abstractAbstract Background: The development of intrinsic and acquired resistance to antineoplastic agents is a major obstacle to successful chemotherapy in ovarian cancers. Identification and characterisation of chemoresponse-associated biomarkers are of paramount importance for novel therapeutic development. Methods: Global RNA expression profiles were obtained by high-throughput microarray analysis. Cell cycle, proliferation rate, and paclitaxel sensitivity of ovarian cancer cells harbouring cyclin A1-inducible expression construct were compared with and without tetracycline induction, as well as when the cyclin A1 expression was suppressed by short inhibiting RNA (siRNA). Cellular senescence was evaluated by b-galactosidase activity staining. Results: Global RNA expression profiling and subsequent correlation studies of gene expression level and drug response has identified that elevated expression of cyclin A1 (CCNA1) was significantly associated with cellular resistance to paclitaxel, doxorubicin and 5-fluorouracil. The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxelmediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity. However, ovarian cancer cells with ectopic expression of cyclin A1 demonstrated slowdown of proliferation and senescence-associated b-galactosidase activity. Conclusions: Our profiling and correlation studies have identified cyclin A1 as one chemoresistance-associated biomarker in ovarian cancer. The results of the characterisation studies suggest that cyclin A1 functions as an oncogene that controls proliferative and survival activities in tumourigenesis and chemoresistance of ovarian cancer.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom152
dc.relation.ispartofpageto163
dc.relation.ispartofjournalEuropean Journal of Cancer
dc.relation.ispartofvolume67
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchOncology and carcinogenesis not elsewhere classified
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchcode3211
dc.subject.fieldofresearchcode321199
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4206
dc.titleCyclin A1 expression and paclitaxel resistance in human ovarian cancer cells
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorNg, Shu Kay Angus


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record